Truist Securities Reiterates Hold on Amgen, Maintains $260 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reiterated a 'Hold' rating on Amgen (NASDAQ:AMGN) and maintained a price target of $260.
September 05, 2023 | 2:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Amgen's stock rating has been reiterated as 'Hold' by Truist Securities with a maintained price target of $260.
The reiteration of the 'Hold' rating and maintained price target by Truist Securities indicates a neutral outlook for Amgen's stock in the short term. This could mean that the analyst believes the stock is fairly valued at its current price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100